Johnson & Johnson (JNJ, Financial) has finalized the acquisition of V-Wave Ltd, a private medical device company. The pharmaceutical giant agreed to purchase V-Wave for an upfront payment of $600 million. This transaction is considered an asset acquisition and will result in approximately $600 million in in-process research and development expenses in the fourth quarter of 2024.
V-Wave, which specializes in cardiovascular disease treatment solutions, will now operate as part of Johnson & Johnson's medtech division. According to previous disclosures, the acquisition is expected to dilute Johnson & Johnson's adjusted earnings per share by around $0.24 in 2024 and $0.06 in 2025.
